Immuron details PROIBS IBS launch via Form 6-K

Immuron Limited submitted a Form 6-K to provide U.S. investors with an announcement it released on the Australian Securities Exchange.

Accepted by SEC EDGAR 10/23/2025 - 08:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Immuron Limited submitted a Form 6-K to provide U.S. investors with an announcement it released on the Australian Securities Exchange. The attached notice is titled “Immuron launch PROIBS for IBS,” indicating the company has announced the launch of a product called PROIBS aimed at irritable bowel syndrome (IBS). The Form 6-K simply furnishes this ASX announcement as an exhibit and states that it is not deemed filed under the Exchange Act nor automatically incorporated by reference into other U.S. securities filings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immuron Limited (IMRN) report in this Form 6-K?

Immuron Limited furnished a Form 6-K to provide a copy of an Australian Securities Exchange announcement titled “Immuron launch PROIBS for IBS.” The Form 6-K mainly serves to share this announcement with U.S. investors.

What is the key announcement mentioned for Immuron Limited (IMRN)?

The key announcement is titled “Immuron launch PROIBS for IBS”, indicating Immuron has announced the launch of PROIBS for irritable bowel syndrome on the Australian Securities Exchange.

Does this Immuron (IMRN) Form 6-K include detailed financial results?

No. The Form 6-K describes that Immuron has attached an Australian Securities Exchange announcement about launching PROIBS for IBS. It does not present detailed financial results in the provided content.

Is the Immuron PROIBS for IBS announcement considered filed under U.S. securities laws?

The document states that this Form 6-K, including the attached announcement titled “Immuron launch PROIBS for IBS,” is furnished and shall not be deemed to be filed for purposes of the Exchange Act.

Can the PROIBS for IBS announcement be automatically incorporated into other Immuron (IMRN) SEC filings?

No. The Form 6-K specifies that it shall not be incorporated by reference into any Securities Act filing, except where another filing expressly includes it by specific reference.

Who signed this Immuron Limited (IMRN) Form 6-K?

The Form 6-K was signed on behalf of Immuron Limited by Phillip Hains, identified as the Company Secretary, dated October 24, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2025

Commission File Number: 001-38104

IMMURON LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

IMMURON LIMITED

EXPLANATORY NOTE

Immuron Limited (the “Company”) published one announcement (the “Public Notices”) to the Australian Securities Exchange on October 24, 2025 titled:

	-	Immuron launch PROIBS for IBS
	-

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Immuron launch PROIBS for IBS

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IMMURON LIMITED
Date: October 24, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3